Top

Journal of Medical Case Reports

Published in:

Open Access 01-12-2011 | Case report

Cutaneous lupus erythematosus after treatment with paclitaxel and bevacizumab for metastatic breast cancer: a case report

Authors: Pia Vihinen, Outi Paija, Atte Kivisaari, Leena Koulu, Heikki Aho

Published in: Journal of Medical Case Reports | Issue 1/2011

Abstract

Introduction

The monoclonal anti-vascular endothelial growth factor antibody bevacizumab is increasingly used in the treatment of several malignant tumors. The usual side effects of this drug are hypertension and proteinuria. Paclitaxel is widely used in the treatment of breast cancer and head and neck carcinomas. Neither of these two drugs typically causes skin disorders. Paclitaxel-related cutaneous lupus erythematosus has been described before, but in earlier cases patients had a history of autoimmune disease.

Case presentation

We report a case of a 65-year-old Caucasian woman who presented with cutaneous lupus erythematosus after receiving paclitaxel-bevacizumab combination treatment as first-line therapy for metastatic breast cancer. Her cutaneous symptoms and increased serum anti-SSA and anti-SSB antibodies disappeared shortly after the discontinuation of therapy.

Conclusion

We conclude that cutaneous lupus erythematosus can also be seen in patients without earlier anamnesis of autoimmune disorders and that, furthermore, bevacizumab might cause atypical cutaneous side effects.

Available only for authorised users

Reefman E, Kuiper H, Jonkman MF, Limburg PC, Kallenberg CG, Bijl M: Skin sensitivity to UVB irradiation in systemic lupus erythematosus is not related to the level of apoptosis induction in keratinocytes. Rheumatology. 2006, 45: 538-544. 10.1093/rheumatology/kei249.CrossRefPubMed

Sarzi-Puttini P, Atzeni F, Capsoni F, Lubrano E, Doria A: Drug-induced lupus erythematosus. Autoimmunity. 2005, 38: 507-518. 10.1080/08916930500285857.CrossRefPubMed

de Agrila D, Dominquez JD, Iglesias L: Taxol-induced acral erythema. Dermatology. 1996, 192: 377-378. 10.1159/000246419.CrossRef

Kupfer I, Balguerie X, Courville P, Chinet P, Joly P: Scleroderma-like cutaneous lesions induced by paclitaxel: a case study. J Am Acad Dermatol. 2003, 48: 279-281. 10.1067/mjd.2003.30.CrossRefPubMed

Hiraki A, Aoe K, Murakami T, Maeda T, Eda R, Takeyama H: Stevens-Johnson syndrome induced by paclitaxel in a patient with squamous cell carcinoma of the lung: a case report. Anticancer Res. 2004, 24: 1135-1137.PubMed

Adachi A, Horikawa T: Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA/Ro antibody. J Dermatol. 2007, 34: 473-476. 10.1111/j.1346-8138.2007.00313.x.CrossRefPubMed

Banerjee S, Dowsett M, Ashworth A, Martin LA: Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol. 2007, 4: 536-550.CrossRefPubMed

Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel for metastatic breast cancer. N Engl J Med. 2007, 357: 2666-2676. 10.1056/NEJMoa072113.CrossRefPubMed

Schöffski P, Dumez H, Clement P, Hoeben A, Prenen H, Wolter P, Joniau S, Roskams T, Van Poppel H: Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Ann Oncol. 2006, 17: 1185-1196. 10.1093/annonc/mdj133.CrossRefPubMed

10.

Chem M, Crowson AN, Woofter M, Luca MB, Magro CM: Docetaxel (Taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases. J Rheumatol. 2004, 31: 818-820.

11.

Gotlib V, Khaled S, Lapko I, Mar N, Saif MW: Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs. 2006, 17: 1227-1229. 10.1097/01.cad.0000231481.07654.fc.CrossRefPubMed

12.

Saif MF, Kim R: Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin Drug Saf. 2007, 6: 175-182. 10.1517/14740338.6.2.175.CrossRefPubMed

13.

Man XY, Yang XH, Cai SQ, Yao YG, Zheng M: Immunolocalization and expression of vascular endothelial growth factor receptors (VEGFRs) and neuropilins (NRPs) on keratinocytes in human epidermis. Mol Med. 2006, 12: 127-136.CrossRefPubMedPubMedCentral

14.

Kikuchi K, Kubo M, Kadono T, Yazawa N, Ihn H, Tamaki K: Serum concentrations of vascular endothelial growth factor in collagen diseases. Br J Dermatol. 1998, 139: 1049-1051. 10.1046/j.1365-2133.1998.02563.x.CrossRefPubMed

Title: Cutaneous lupus erythematosus after treatment with paclitaxel and bevacizumab for metastatic breast cancer: a case report
Authors: Pia Vihinen
Outi Paija
Atte Kivisaari
Leena Koulu
Heikki Aho
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: Journal of Medical Case Reports / Issue 1/2011
Electronic ISSN: 1752-1947
DOI: https://doi.org/10.1186/1752-1947-5-243

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Cutaneous lupus erythematosus after treatment with paclitaxel and bevacizumab for metastatic breast cancer: a case report

Abstract

Introduction

Case presentation

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Case presentation

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2011

Use of intra-medullary stacked nailing in the reduction of proximal plastic deformity in a pediatric Monteggia fracture: a case report

Epidural varicosis as a possible cause of radicular pain: a case report

Reversible cerebral vasoconstriction syndrome in a patient taking citalopram and Hydroxycut: a case report

Proximal femoral fracture in a man resulting from modern clipless pedals: a case report

Management of a rare case of arrhythmogenic right ventricular dysplasia in pregnancy: a case report

Plasmablastic lymphoma in the ano-rectal junction presenting in an immunocompetent man: a case report